Clinical Trial Update: A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients with Chronic Kidney Disease-Associated Pruritus [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of HSK21542 for chronic kidney disease-associated pruritus in hemodialysis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease-associated Pruritus

Drugs mentioned

• HSK21542

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: Pruritus, Hemodialysis Patients with Moderate-to-Severe Pruritus | Phase 3 | Status: COMPLETED